Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Beijing InnoCare Raises $160 Million for Cancer/Autoimmune Drugs

publication date: Jan 4, 2019

Beijing InnoCare Pharma announced it completed a $160 million financing to advance its portfolio of novel treatments for cancer and autoimmune diseases. In February 2018, InnoCare raised $55 million in a funding led by Vivo Capital. The company uses internal R&D, in-licensings and international collaborations to develop first-in-class and/or best-in-class drugs. It has three cancer candidates in clinical trials, including several tests for its BTK inhibitor. The latest investment round was led by Loyal Valley Capital. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021